评估国际肺癌研究协会对通过气隙扩散的腺癌采用的新分级系统。

IF 4 2区 医学 Q2 ONCOLOGY Translational lung cancer research Pub Date : 2024-08-31 Epub Date: 2024-08-27 DOI:10.21037/tlcr-24-265
Kuan Xu, Yilv Lv, Tangbing Chen, Yuchen Han, Hanqing Huang, Hong Yu, Bo Ye
{"title":"评估国际肺癌研究协会对通过气隙扩散的腺癌采用的新分级系统。","authors":"Kuan Xu, Yilv Lv, Tangbing Chen, Yuchen Han, Hanqing Huang, Hong Yu, Bo Ye","doi":"10.21037/tlcr-24-265","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The International Association for the Study of Lung Cancer (IASLC) pathology panel has proposed a new grading system for invasive lung adenocarcinoma (LADC). This study aims to validate this novel grading system for invasive LADC using propensity score matching (PSM), with a specific focus on patients exhibiting spread through air space (STAS).</p><p><strong>Methods: </strong>We retrospectively analyzed the clinicopathologic features of a large cohort of 910 non-mucinous LADCs with STAS from 2017 to 2020 and classified them according to the novel grading system. We applied PSM to adjust for potential confounders between the grading groups. Kaplan-Meier and Cox proportional hazards models were adopted for prognostic evaluation.</p><p><strong>Results: </strong>The results showed that the IASLC grading system (grades 2 and 3) stratified well in terms of recurrence-free survival (RFS) and overall survival (OS) (P<i>=</i>0.02 and P<i>=</i>0.02, respectively) after matching, with Grade 3 being an independent predictor of RFS [hazard ratio (HR), 1.533; P<i>=</i>0.02] and OS (HR, 2.765; P<i>=</i>0.02) in multivariable models. The concordance index (C-index) and area under the curve (AUC) of the IASLC system were 0.719 and 0.754 for recurrence and 0.844 and 0.891 for death, respectively. In addition, anaplastic lymphoma kinase (<i>ALK</i>) fusion and tumor protein p53 (<i>TP53</i>) mutations were detected more frequently in grade 3 tumors, while epidermal growth factor receptor (<i>EGFR</i>) mutations were more prevalent in grade 2 tumors. The IASLC grade did not predict the benefit of adjuvant chemotherapy (ACT).</p><p><strong>Conclusions: </strong>This study suggests that the new IASLC grading system is a valuable prognostic tool for patients with STAS-positive LADC.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384489/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space.\",\"authors\":\"Kuan Xu, Yilv Lv, Tangbing Chen, Yuchen Han, Hanqing Huang, Hong Yu, Bo Ye\",\"doi\":\"10.21037/tlcr-24-265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The International Association for the Study of Lung Cancer (IASLC) pathology panel has proposed a new grading system for invasive lung adenocarcinoma (LADC). This study aims to validate this novel grading system for invasive LADC using propensity score matching (PSM), with a specific focus on patients exhibiting spread through air space (STAS).</p><p><strong>Methods: </strong>We retrospectively analyzed the clinicopathologic features of a large cohort of 910 non-mucinous LADCs with STAS from 2017 to 2020 and classified them according to the novel grading system. We applied PSM to adjust for potential confounders between the grading groups. Kaplan-Meier and Cox proportional hazards models were adopted for prognostic evaluation.</p><p><strong>Results: </strong>The results showed that the IASLC grading system (grades 2 and 3) stratified well in terms of recurrence-free survival (RFS) and overall survival (OS) (P<i>=</i>0.02 and P<i>=</i>0.02, respectively) after matching, with Grade 3 being an independent predictor of RFS [hazard ratio (HR), 1.533; P<i>=</i>0.02] and OS (HR, 2.765; P<i>=</i>0.02) in multivariable models. The concordance index (C-index) and area under the curve (AUC) of the IASLC system were 0.719 and 0.754 for recurrence and 0.844 and 0.891 for death, respectively. In addition, anaplastic lymphoma kinase (<i>ALK</i>) fusion and tumor protein p53 (<i>TP53</i>) mutations were detected more frequently in grade 3 tumors, while epidermal growth factor receptor (<i>EGFR</i>) mutations were more prevalent in grade 2 tumors. The IASLC grade did not predict the benefit of adjuvant chemotherapy (ACT).</p><p><strong>Conclusions: </strong>This study suggests that the new IASLC grading system is a valuable prognostic tool for patients with STAS-positive LADC.</p>\",\"PeriodicalId\":23271,\"journal\":{\"name\":\"Translational lung cancer research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384489/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational lung cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tlcr-24-265\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-265","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:国际肺癌研究协会(IASLC)病理小组提出了一种新的浸润性肺腺癌(LADC)分级系统。本研究旨在利用倾向评分匹配(PSM)验证这一新型浸润性肺腺癌分级系统,特别关注表现出气隙扩散(STAS)的患者:我们回顾性分析了2017年至2020年910例STAS非黏液性LADC大样本的临床病理特征,并根据新型分级系统进行了分类。我们应用PSM调整了分级组间的潜在混杂因素。采用Kaplan-Meier和Cox比例危险模型进行预后评估:结果显示,IASLC分级系统(2级和3级)在匹配后对无复发生存期(RFS)和总生存期(OS)进行了良好的分层(分别为P=0.02和P=0.02),在多变量模型中,3级是RFS[危险比(HR),1.533;P=0.02]和OS(HR,2.765;P=0.02)的独立预测因子。IASLC系统的一致性指数(C-index)和曲线下面积(AUC)分别为:复发为0.719和0.754,死亡为0.844和0.891。此外,在3级肿瘤中更常检测到无性淋巴瘤激酶(ALK)融合和肿瘤蛋白p53(TP53)突变,而表皮生长因子受体(EGFR)突变在2级肿瘤中更为普遍。IASLC分级并不能预测辅助化疗(ACT)的疗效:本研究表明,新的IASLC分级系统是STAS阳性LADC患者的重要预后工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space.

Background: The International Association for the Study of Lung Cancer (IASLC) pathology panel has proposed a new grading system for invasive lung adenocarcinoma (LADC). This study aims to validate this novel grading system for invasive LADC using propensity score matching (PSM), with a specific focus on patients exhibiting spread through air space (STAS).

Methods: We retrospectively analyzed the clinicopathologic features of a large cohort of 910 non-mucinous LADCs with STAS from 2017 to 2020 and classified them according to the novel grading system. We applied PSM to adjust for potential confounders between the grading groups. Kaplan-Meier and Cox proportional hazards models were adopted for prognostic evaluation.

Results: The results showed that the IASLC grading system (grades 2 and 3) stratified well in terms of recurrence-free survival (RFS) and overall survival (OS) (P=0.02 and P=0.02, respectively) after matching, with Grade 3 being an independent predictor of RFS [hazard ratio (HR), 1.533; P=0.02] and OS (HR, 2.765; P=0.02) in multivariable models. The concordance index (C-index) and area under the curve (AUC) of the IASLC system were 0.719 and 0.754 for recurrence and 0.844 and 0.891 for death, respectively. In addition, anaplastic lymphoma kinase (ALK) fusion and tumor protein p53 (TP53) mutations were detected more frequently in grade 3 tumors, while epidermal growth factor receptor (EGFR) mutations were more prevalent in grade 2 tumors. The IASLC grade did not predict the benefit of adjuvant chemotherapy (ACT).

Conclusions: This study suggests that the new IASLC grading system is a valuable prognostic tool for patients with STAS-positive LADC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
期刊最新文献
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma. A nomogram predicting the risk of extrathoracic metastasis at initial diagnosis of T≤3cmN0 lung cancer. Are PD-1T TILs merely an expensive and unuseful whim as biomarker? Assessing the transportability of radiomic models for lung cancer diagnosis: commercial vs. open-source feature extractors. Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development-are we close to the finish line?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1